Fintel reports that on March 13, 2025, RBC Capital initiated coverage of Natera (NasdaqGS:NTRA) with a Outperform ...
Natera (NasdaqGS:NTRA) announced a strategic expansion of its Board of Directors with the appointment of Monica Bertagnolli. This decision occurred against a backdrop of significant market volatility, ...
Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 5.2% in the afternoon session after stocks rebounded, ...
RBC Capital analyst Conor McNamara initiated coverage of Natera (NTRA) with an Outperform rating and $251 price target The firm says Natera is ...
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the HEROES clinical trial. HEROES is a multi-center ...
Natera has a twelve month low of $83.13 and a twelve month high of $183.00. The stock has a 50-day simple moving average of $165.61 and a two-hundred day simple moving average of $148.09.
AUSTIN, Texas - Natera, Inc. (NASDAQ: NTRA), a healthcare diagnostics company with impressive revenue growth of 57% over the last twelve months and a market capitalization of $19 billion ...
Shares of Natera stock opened at $140.66 on Wednesday. The stock has a market cap of $19.02 billion, a price-to-earnings ratio of -79.92 and a beta of 1.80. The company has a debt-to-equity ratio ...
The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the HEROES clinical trial.
HEROES is Natera's first clinical trial using Signatera to guide de-escalation of therapy in patients with metastatic HER2+ breast cancer Approximately 170 patients are expected to enroll in up to ...